Skip to Content

Clinical perspective of the COAST-study for unresectable Stage III NSCLC

In this MEDtalk Roy S. Herbst, Medical Oncologist answers questions about the COAST-study of patients with locally advanced, unresectable, stage III NSCLC with durmavumab alone or in combination with novel agents.

Roy S. Herbst

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top